Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio (TELA) to $1.25 from $2 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results which missed its estimate on the top-line and on the operating loss side of things. Revenue guidance for the year was lowered, which is certainly a disappointing update, Piper adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA: